Compare WSR & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSR | COLL |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.9M | 1.1B |
| IPO Year | 2002 | 2015 |
| Metric | WSR | COLL |
|---|---|---|
| Price | $18.96 | $36.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $19.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 677.0K | 424.2K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 31.94 | N/A |
| EPS | 0.08 | ★ 0.40 |
| Revenue | $160,859,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $2.77 | $8.01 |
| Revenue Next Year | $4.21 | N/A |
| P/E Ratio | $237.00 | ★ $90.50 |
| Revenue Growth | 4.26 | ★ 23.62 |
| 52 Week Low | $11.43 | $29.19 |
| 52 Week High | $19.10 | $50.79 |
| Indicator | WSR | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 59.11 |
| Support Level | $18.90 | $33.80 |
| Resistance Level | $19.01 | $48.74 |
| Average True Range (ATR) | 0.03 | 1.35 |
| MACD | -0.03 | 0.30 |
| Stochastic Oscillator | 27.50 | 81.55 |
Whitestone REIT is a real estate investment trust (REIT) that owns and operates commercial properties in culturally diverse metropolitan markets. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business-friendly locations in and around Austin, Scottsdale, Dallas, Houston, Phoenix, Arizona, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.